News
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have...
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine...
ChromaDex’s Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today...
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 LOS ANGELES - ChromaDex Corp....
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m....
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial...
ChromaDex to Participate in the 17th Annual LD Micro Main Event
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel,...
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
This award recognizes Dr. Nkrumah-Elie's dedication to advancing scientific excellence for ChromaDex's leading external research program and mentorship in the dietary supplement industry LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide...
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat...
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate...